2,7-Disubstituted-pyrrolo[2,1- f ][1,2,4]triazines: New variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity

Journal of Medicinal Chemistry

Volumn 54, Issue 18, 2011, Pages 6328-6341

  Ott, Gregory R ^a   Wells, Gregory J ^a   Thieu, Tho V ^a   Quail, Matthew R ^a   Lisko, Joseph G ^a   Mesaros, Eugen F ^a   Gingrich, Diane E ^a   Ghose, Arup K ^a   Wan, Weihua ^a   Lu, Lihui ^a   Cheng, Mangeng ^a   Albom, Mark S ^a   Angeles, Thelma S ^a   Huang, Zeqi ^a   Aimone, Lisa D ^a   Ator, Mark A ^a   Ruggeri, Bruce A ^a   Dorsey, Bruce D ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,7 DISUBSTITUTED PYRROLO(2,1 F)(1,2,4)TRIAZINE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; PHOSPHOTRANSFERASE INHIBITOR; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; IN VIVO STUDY; MOLECULAR MIMICRY; NONHUMAN; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MICE; MICE, SCID; MICROSOMES, LIVER; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES;

EID: 80052805088     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200758k     Document Type: Article

References (49)

1. Gostissa, M.; Alt, F. W.; Chiarle, R. Mechanisms that Promote and Suppress Chromosomal Translocations in Lymphocytes Annu. Rev. Immunol. 2011, 29, 319-350
2. Druker, B. J. Imatinib as a paradigm of targeted therapies Adv. Cancer Res. 2004, 91, 1-30 (Pubitemid 39140955)
3. Deininger, M.; Buchdunger, E.; Druker, B. J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 2005, 105, 2640-2653 (Pubitemid 40446252)
4. Chiarle, R.; Voena, C.; Ambrogio, C.; Piva, R.; Inghirami, G. The anaplastic lymphoma kinase in the pathogenesis of cancer Nature Rev. Cancer 2008, 8 (1) 11-23
5. Webb, T. R.; Slavish, J.; George, R. E.; Look, A. T.; Xue, L.; Jiang, Q.; Cui, X.; Rentrop, W. B.; Morris, S. W. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy Expert Rev. Anticancer Ther. 2009, 9 (3) 331-356
6. Chiarle, R.; Gong, J. Z.; Guasparri, I.; Pesci, A.; Cai, J.; Liu, J.; Simmons, W. J.; Dhall, G.; Howes, J.; Piva, R.; Inghirami, G. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors Blood 2003, 101 (5) 1919-1927 (Pubitemid 36237594)
7. Turner, S. D.; Tooze, R.; Maclennan, K.; Alexander, D. R. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase Oncogene 2003, 22 (49) 7750-7761 (Pubitemid 37485534)
8. Jager, R.; Hahne, J.; Jacob, A.; Egert, A.; Schenkel, J.; Wernert, N.; Schorle, H.; Wellmann, A. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas Anticancer Res. 2005, 5, 3191-3196 (Pubitemid 41105188)
9. Piva, R.; Chiarle, R.; Manazza, A. D.; Taulli, R.; Simmons, W.; Ambrogio, C.; D'Escamard, V.; Pellegrino, E.; Ponzetto, C.; Palestro, G.; Inghirami, G. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas Blood 2006, 107 (2) 689-697 (Pubitemid 43076395)
10. Wan, W.; Albom, M. S.; Lu, L.; Quail, M. R.; Becknell, N. C.; Weinberg, L. R.; Reddy, D. R.; Holskin, B. P.; Angeles, T. S.; Underiner, T. L.; Meyer, S. L.; Hudkins, R. L.; Dorsey, B. D.; Ator, M. A.; Ruggeri, B. A.; Cheng, M. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells Blood 2006, 107 (4) 1617-1623 (Pubitemid 43242400)
11. Galkin, A. V.; Melnick, J. S.; Kim, S.; Hood, T. L.; Li, N.; Li, L.; Xia, G.; Steensma, R.; Chopiuk, G.; Jiang, J.; Wan, Y.; Ding, P.; Liu, Y.; Sun, F.; Schultz, P. G.; Gray, N. S.; Warmuth, M. Identification of NVP-TAE684, a potent, selective and efficacious inhibitor of NPM-ALK Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 270-275 (Pubitemid 46068021)
12. Christensen, J. G.; Zou, H.; Arango, M.; Li, Q.; Lee, J. H.; McDonnell, S. R.; Yamazaki, S.; Alton, G.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066, a novel Inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol. Cancer. Ther. 2007, 6, 3389-3395
13. Soda, M.; Choi, Y. L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 2007, 448 (7153) 561-566 (Pubitemid 47206930)
14. Rikova, K.; Guo, A.; Qingfu, Z.; Possemato, A.; Yu, J.; Haack, H.; Nardone, J.; Lee, K.; Reeves, C.; Li, Y.; Hu, Y.; Tan, Z.; Stokes, M.; Sullivan, L.; Mitchell, J.; Wetzel, R.; MacNeill, J.; Ren, J. M.; Yuan, J.; Bakalarski, C. E.; Villen, J.; Kornhauser, J. M.; Smith, B.; Li, D.; Zhou, X.; Gygi, S. P.; Gu, T.-L.; Polakiewicz, R. D.; Rush, J.; Comb, M. J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 2007, 131 (6) 1190-1203 (Pubitemid 350235027)
15. Choi, Y. L.; Takeuchi, K.; Soda, M.; Inamura, K.; Togashi, Y.; Hatano, S.; Enomoto, M.; Hamada, T.; Haruta, H.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Ueno, T.; Takada, S.; Yamashita, Y.; Sugiyama, Y.; Ishikawa, Y.; Mano, H. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer Cancer Res. 2008, 68 (13) 4971-4976
16. Inamura, K.; Takeuchi, K.; Togashi, Y.; Nomura, K.; Ninomiya, H.; Okui, M.; Satoh, Y.; Okumura, S.; Nakagawa, K.; Soda, M.; Choi, Y. L.; Niki, T.; Mano, H.; Ishikawa, Y. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers J. Thorac. Oncol. 2008, 3, 13-17
17. Wong, D. W.; Leung, E. L.; So, K. K.; Tam, I. Y.; Sihoe, A. D.; Cheng, L. C.; Ho, K. K.; Au, J. S.; Chung, L. P.; Wong, M. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS Cancer 2009, 115 (8) 1723-1733
18. Inamura, K.; Takeuchi, K.; Togashi, Y.; Hatano, S.; Ninomiya, H.; Motoi, N.; Mun, M. Y.; Sakao, Y.; Okumura, S.; Nakagawa, K.; Soda, M.; Choi, Y. L.; Mano, H.; Ishikawa, Y. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset Mod. Pathol. 2009, 22 (4) 508-515
19. Soda, M; Takada, S; Takeuchi, K; Choi, Y. L.; Enomoto, M; Ueno, T; Haruta, H; Hamada, T; Yamashita, Y.; Ishikawa, Y.; Sugiyama, Y.; Mano, H. A mouse model for EML4-ALK positive lung cancer Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 19893-19897
20. Mossé, Y. P.; Laudenslager, M.; Longo, L.; Cole, K. A.; Wood, A.; Attiyeh, E. F.; Laquaglia, M. J.; Sennett, R.; Lynch, J. E.; Perri, P.; Laureys, G.; Speleman, F.; Kim, C.; Hou, C.; Hakonarson, H.; Torkamani, A.; Schork, N. J.; Brodeur, G. M.; Tonini, G. P.; Rappaport, E.; Devoto, M.; Maris, J. M. Identification of ALK as a major familial neuroblastoma predisposition gene Nature 2008, 455 (7215) 930-936
21. Chen, Y.; Takita, J.; Choi, Y. L.; Kato, M.; Ohira, M.; Sanada, M.; Wang, L.; Soda, M.; Kikuchi, A.; Igarashi, T.; Nakagawara, A.; Hayashi, Y.; Mano, H.; Ogawa, S. Oncogenic mutations of ALK kinase in neuroblastoma Nature 2008, 455 (7215) 971-974
22. George, R. E.; Sanda, T.; Hanna, M.; Fröhling, S.; Luther, W.; Zhang, J.; Ahn, Y.; Zhou, W.; London, W. B.; McGrady, P.; Xue, L.; Zozulya, S.; Gregor, V. E.; Webb, T. R.; Gray, N. S.; Gilliland, D. G.; Diller, L.; Greulich, H.; Morris, S. W.; Meyerson, M.; Look, A. T. Activating mutations in ALK provide a therapeutic target in neuroblastoma Nature 2008, 455 (7215) 975-978
23. Janoueix-Lerosey, I.; Lequin, D.; Brugières, L.; Ribeiro, A.; de Pontual, L.; Combaret, V.; Raynal, V.; Puisieux, A.; Schleiermacher, G.; Pierron, G.; Valteau-Couanet, D.; Frebourg, T.; Michon, J.; Lyonnet, S.; Amiel, J.; Delattre, O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma Nature 2008, 455 (7215) 967-970
24. Kwak, E. L.; Bang, Y.-J.; Camidge, R.; Shaw, A. T.; Solomon, B.; Maki, R. G.; Ou, S.-H. I.; Dezube, B. J.; Janne, P. A.; Costa, D. B.; Varella-Garcia, M.; Kim, W.-H.; Lynch, T. J.; Fidias, P.; Stubbs, H.; Engelman, J. A.; Sequist, L. V.; Tan, W.; Gandhi, L.; Mino-Kenudson, M.; Wei, G. C.; Shreeve, M.; Ratain, M. J.; Settleman, J.; Christensen, J. G.; Haber, D. A.; Wilner, K.; Salgia, R.i; Shapiro, G. I.; Clark, J. W.; Iafrate, A. J. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer New Engl. J. Med. 2010, 363, 1693-1703
25. Li, R.; Xue, L.; Zhu, T.; Jiang, Q.; Cui, X.; Yan, Z.; McGee, D.; Wang, J.; Gantla, V. R.; Pickens, J. C.; McGrath, D.; Chucholowski, A.; Morris, S. W.; Webb, T. R. Design and Synthesis of 5-Aryl-pyridone-carboxamides as Inhibitors of Anaplastic Lymphoma Kinase J. Med. Chem. 2006, 49 (3) 1006-1015 (Pubitemid 43221648)
26. Sabbatini, P.; Korenchuk, S.; Rowand, J. L.; Groy, A.; Liu, Q.; Leperi, D.; Atkins, C.; Dumble, M.; Yang, J.; Anderson, K.; Kruger, R. G.; Gontarek, R. R.; Maksimchuk, K. R.; Suravajjala, S.; Lapierre, R.R.; Shotwell, J. B.; Wilson, J. W.; Chamberlain, S. D.; Rabindran, S. K.; Kumar, R. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers Mol. Cancer Ther. 2009, 8 (10) 2811-2820
27. Bossi, R. T.; Saccardo, M. B.; Ardini, E.; Menichincheri, M.; Rusconi, L.; Magnaghi, P.; Orsini, P.; Avanzi, N.; Lombardi Borgia, A.; Nesi, M.; Bandiera, T.; Fogliatto, G.; Bertrand, J. A. Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP-Competitive Inhibitors Biochemistry 2010, 49 (32) 6813-6825
28. Deng, X.; Wang, J.; Zhang, J.; Sim, T.; Kim, N. D.; Sasaki, T.; Luther, W., II; George, R. E.; Janne, P. A.; Gray, N. S. Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors ACS Med. Chem. Lett. 2011, 2, 379-384
29. Sakamoto, H.; Tsukaguchi, T.; Hiroshima, S.; Kodama, T.; Kobayashi, T.; Fukami, T. A.; Oikawa, N.; Tsukuda, T.; Ishii, N.; Aoki, Y. CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant Cancer Cell 2011, 19 (5) 679-690
30. For recent reviews see ref 5 and Li, R.; Morris, S. W. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy Med. Res. Rev. 2008, 28 (3) 372-412 (Pubitemid 351590540)
31. Katayama, R.; Khan, T. M.; Benes, C.; Lifshits, E.; Ebi, H.; Rivera, V. M.; Shakespeare, W. C.; Iafrate, A. J.; Engelman, J. A.; Shaw, A. T. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (18) 7535-7540
32. Ardini, E.; Menichincheri, M.; De Ponti, C.; Amboldi, N.; Ballinari, D.; Saccardo, M. B.; Croci, V.; Stellari, F.; Texido, G.; Orsini, P.; Perrone, E.; Bandiera, T.; Borgia, A. L.; Lansen, J.; Isacchi, A.; Colotta, F.; Pesenti, E.; Magnaghi, P.; Galvani, A. A highly potent, selective and orally available ALK inhibitor with demonstrated antitumor efficacy in ALK dependent lymphoma and non small cell lung cancer models. Proc. Am. Assoc. Cancer Res. April, 2009, Abstract 3737.
33. Milkiewicz, K. L.; Weinberg, L. R.; Albom, M. S.; Angeles, T. S.; Cheng, M.; Ghose, A. K.; Roemmele, R. C.; Theroff, J. P.; Underiner, T. L.; Zificsak, C. A.; Dorsey, B. D. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3- b ]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase Bioorg. Med. Chem. 2010, 18, 4351-4362
34. Ott, G. R.; Tripathy, R.; Cheng, M.; McHugh, R.; Anzalone, A. V.; Underiner, T. L.; Curry, M. A.; Quail, M. R.; Lu, L.; Wan, W.; Angeles, T. S.; Albom, M. S.; Aimone, L. D.; Ator, M. A.; Ruggeri, B. A.; Dorsey, B. D. Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity ACS Med. Chem. Lett. 2010, 1, 493-498
35. Mesaros, E. F.; Burke, J. P.; Parrish, J. D.; Dugan, B. J.; Anzalone, A. V.; Angeles, T. S.; Albom, M. S.; Aimone, L. D.; Quail, M. R.; Wan, W.; Lu, L.; Huang, Z.; Ator, M. A.; Ruggeri, B. A.; Cheng, M.; Ott, G. R.; Dorsey, B. D. Novel 2,3,4,5-tetrahydro-benzo[ d ]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models Bioorg. Med. Chem. Lett. 2011, 21, 463-466
36. Choi, H.-S.; Wang, Z.; Richmond, W.; He, X.; Yang, K.; Jiang, T.; Sim, T.; Karanewsky, D.; Gu, X.-J.; Zhou, V.; Liu, Y.; Ohmori, O.; Caldwell, J.; Gray, N.; He, Y. Design and synthesis of 7 H -pyrrolo[2,3- d ]pyrimidines as focal adhesion kinase inhibitors. Part 1, Bioorg. Med. Chem. Lett. 2006, 16, 2173-2176. (Pubitemid 43351073)
37. Lum, C.; Kahl, J.; Kessler, L.; Kucharski, J.; Lundstrom, J.; Miller, S.; Nakanishi, H.; Pei, Y.; Pryor, K.; Roberts, E.; Sebo, L.; Sullivan, R.; Urban, J.; Wang, Z. 2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3) Bioorg. Med. Chem. Lett. 2008, 18, 3578-3581 (Pubitemid 351787556)
38. Lu, L.; Ghose, A. K.; Quail, M. R.; Albom, M. S.; Durkin, J. T.; Holskin, B. P.; Angeles, T. S.; Meyer, S. L.; Ruggeri, B. A.; Cheng, M. ALK Mutants in the Kinase Domain Exhibit Altered Kinase Activity and Differential Sensitivity to Small Molecule ALK Inhibitors Biochemistry 2009, 48, 3600-3609
39. Choi, Y. L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H.; Ishikawa, Y.; Kimura, H.; Mitsudomi, T.; Tanio, Y.; Mano, H. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors New Engl. J. Med. 2010, 363 (18) 1734-1739
40. Lee, C. C.; Jia, Y.; Li, N.; Sun, X.; Ng, K.; Ambing, E.; Gao, M.-Y.; Hua, S.; Chen, C.; Kim, S.; Michellys, P.-Y.; Lesley, S. A.; Harris, J.; Spraggon, G. Crystal Structure of the Anaplastic Lymphoma Kinase Catalytic Domain Biochem. J. 2010, 430, 425-437 see also ref 27
41. Hayashi, M.; Araki, A.; Maeba, I. C-Nucleosides. 17. A synthesis of 2-substituted 7-(β- d -ribofuranosyl)pyrrolo[2,1- f ]-1,2,4-triazines. A new type of "purine like" C-nucleoside Heterocycles 1992, 34, 569-574
42. Patil, S. A.; Otter, B. A.; Klein, R. S. 4-Aza-7,9-dideazaadenosine, a new cytotoxic synthetic C-nucleoside analog of adenosine Tetrahedron Lett. 1994, 35, 5339-5342 (Pubitemid 24253210)
43. Hunt, J. T.; Mitt, T.; Borzilleri, R.; Gullo-Brown, J.; Fargnoli, J.; Fink, B.; Han, W.-C.; Mortillo, S.; Vite, G.; Wautlet, B.; Wong, T.; Zheng, X.; Bhide, R. Discovery of the pyrrolo[2,1- f ][1,2,4]triazine nucleus as a new kinase inhibitor template J. Med. Chem. 2004, 47, 4054-4059 (Pubitemid 38970966)
44. Bhide, R. S.; Cai, Z.-W.; Zhang, Y.-Z.; Qian, L.; Wei, D.; Barbosa, S.; Lombardo, L. J.; Borzilleri, R. M.; Zheng, X.; Wu, L. I.; Barrish, J. C.; Kim, S.-H.; Leavitt, K.; Mathur, A.; Leith, L.; Chao, S.; Wautlet, B.; Mortillo, S.; Jayaseelan, R., Sr.; Kukral, D.; Hunt, J.; Kamath, A.; Fura, A.; Vyas, V.; Marathe, P.; D'Arienzo, C.; Derbin, G.; Fargnoli, J. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1 H -indol-5-yloxy)-5-methylpyrrolo[2,1- f ][1,2,4]triazin-6-yloxy)propanol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor J. Med. Chem. 2006, 49, 2143-2146
45. Schroeder, G. M.; Chen, X.-T.; Williams, D. K.; Nirschl, D.; Cai, Z.-W.; Wei, D.; Tokarski, J. S.; An, Y.; Sack, J.; Chen, Z.; Huynh, T.; Vaccaro, W.; Poss, M.; Wautlet, B.; Gullo-Brown, J.; Kellar, K.; Manne, V.; Hunt, J. T.; Wong, T. W.; Lombardo, L. J.; Fargnoli, J.; Borzilleri, R. M. Identification of pyrrolo[2,1- f ][1,2,4]triazine-based inhibitors of Met kinase Bioorg. Med. Chem. Lett. 2007, 18, 1945-1951
46. Wittman, M. D.; Carboni, J. M.; Yang, Z.; Lee, F. Y.; Antman, M.; Attar, R.; Balimane, P.; Chang, C.; Chen, C.; Discenza, L.; Frennesson, D.; Gottardis, M. M.; Greer, A.; Hurlburt, W.; Johnson, W.; Langley, D. R.; Li, A.; Li, J.; Liu, P.; Mastalerz, H.; Mathur, A.; Menard, K.; Patel, K.; Sack, J.; Sang, X.; Saulnier, M.; Smith, D.; Stefanski, K.; Trainor, G.; Velaparthi, U.; Zhang, G.; Zimmermann, K.; Vyas, D. M. Discovery of a 2,4-Disubstituted Pyrrolo[1,2- f ][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development J. Med. Chem. 2009, 52, 7360-7363
47. For full synthetic procedures for the synthesis of 11 and 15 see: Thieu, T; Sclafani, J. A.; Levy, D. V.; McLean, A.; Breslin, H. J.; Ott, G. R.; Bakale, R.; Dorsey, B. D. Discovery and Process Synthesis of Novel 2,7-Pyrrolo[2,1- f ][1,2,4]triazines Org. Lett. 2011, 13, 4204-4207
48. Mulvihill, M. J.; Ji, Q.-S.; Coate, H. R.; Cooke, A.; Dong, H.; Feng, L.; Foreman, K.; Rosenfeld-Franklin, M.; Honda, A.; Mak, G.; Mulvihill, K. M.; Nigro, A. I.; O'Connor, M.; Pirrit, C.; Steinig, A. G.; Siu, K.; Stolz, K. M.; Sun, Y.; Tavares, P. A. R.; Yao, Y.; Gibson, N. W. Novel 2-phenylquinolin-7-yl- derived imidazo[1,5- a ]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors Bioorg. Med. Chem. 2008, 16, 1359-1375 (Pubitemid 351191767)
49. Zificsak, C. A.; Theroff, J. P.; Aimone, L. D.; Albom, M. S.; Angeles, T. S.; Cheng, M.; Mesaros, E. F.; Ott, G. R.; Quail, M. R.; Underiner, T. L.; Wan, W.; Dorsey, B. D. Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 3877-3880